

Childhood 25-hydroxy-vitamin D levels predict early cardiovascular outcomes in adulthood: the Cardiovascular Risk in Young Finns Study

Jussi Niemelä ^{1,2,*†}, Tomi T. Laitinen ^{3,4,5†}, Joel Nuotio ^{2,3,4},
Katja Pahkala ^{3,4,5}, Suvi Rovio ^{3,4,6}, Jorma Viikari ^{7,8}, Mika Kähönen ^{9,10},
Terho Lehtimäki ¹¹, Britt-Marie Loo ¹², Tomi P. Laitinen ¹³,
Eero Jokinen ¹⁴, Päivi Tossavainen ¹⁵, Costan G. Magnussen ^{3,4,16},
Markus Juonala ^{7,8}, and Olli Raitakari ^{3,4,17,18}

¹Department of Paediatrics and Adolescent Medicine, Turku University Hospital, University of Turku, Savitehtaankatu 5, Turku FI-20520, Finland; ²Heart Center, Turku University Hospital, University of Turku, Savitehtaankatu 5, Turku FI-20520, Finland; ³Centre for Population Health Research, University of Turku, Turku University Hospital, Turku, Finland; ⁴Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland; ⁵Paavo Nurmi Centre and Unit for Health and Physical Activity, University of Turku, Turku, Finland; ⁶Department of Public Health, University of Turku, Turku University Hospital, Turku, Finland; ⁷Department of Medicine, University of Turku, Turku, Finland; ⁸Division of Medicine, Turku University Hospital, Turku, Finland; ⁹Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland; ¹⁰Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ¹¹Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ¹²Joint Clinical Biochemistry Laboratory, Turku University Hospital, University of Turku, Turku, Finland; ¹³Department of Clinical Physiology, University of Eastern Finland, Kuopio University Hospital, Finland; ¹⁴Department of Pediatric Cardiology, Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland; ¹⁵Department of Paediatrics, University of Oulu, Oulu, Finland; ¹⁶Baker Heart and Diabetes Institute, Melbourne, Australia; ¹⁷Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland; and ¹⁸InFLAMES Research Flagship, University of Turku, Turku, Finland

Received 10 January 2025; revised 1 April 2025; accepted 24 April 2025; online publish-ahead-of-print 29 April 2025

Keywords

Atherosclerosis • Cardiovascular disease • Childhood • Vitamin D levels • Mortality • Prevention • Risk factors

Observational studies among adults have suggested that low serum vitamin D levels are related to increased cardiovascular events.¹ We have previously shown that low childhood vitamin D levels associate with increased adult carotid artery intima-media thickness,² a phenotype strongly associated with conventional risk factors. However, whether low vitamin D levels in childhood predict adult-onset cardiovascular events is unknown. Therefore, we describe the relationship between low childhood vitamin D levels and adult-onset atherosclerotic cardiovascular disease (ASCVD) events.

Subjects ($n = 3516$) were participants of the prospective cardiovascular risk in Young Finns study with serum concentrations of 25-hydroxy (OH) vitamin D measured in 2010 from stored frozen samples collected in 1980 when aged 3–18 years.² Conventional childhood risk factors such as body mass index (BMI), LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, consumptions of fruits, vegetables and fish, physical activity, socioeconomic status, and smoking were

measured.² Linkages to national registries covering all Finnish citizens, including the Care Register for Health Care and the National Death Index, were used to ascertain ASCVD outcomes.³ The Cox proportional hazard model was used to analyse the associations of varying cut points of low childhood 25-OH-vitamin D levels and adult ASCVD events, adjusted for age, sex, and childhood risk factors. There was no apparent sex $\times$ childhood vitamin D interaction ($P = 0.22$ for interaction term). Analyses were performed using SAS software version 9.4. Statistical significance was inferred at a two-tailed P -value of <0.05 . All participants and/or their legal guardians gave written informed consent, and the study was conducted in compliance with the Declaration of Helsinki and approved by the Joint Commission on Ethics of the University of Turku and the Turku University Central Hospital.

The baseline age of the participants was 10.5 ± 5.0 years, and 50.9% of the participants were females. In childhood, mean BMI was 17.9 ± 3.1 kg/m², and mean 25-OH-vitamin D concentration was $51.3 \pm$

* Corresponding author. Tel: +358 2 3330000, Fax: +358 2 3337270, Email: jukani@utu.fi

† The first two authors contributed equally to the study.

© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Table 1 Hazard ratios and 95% confidence intervals for cardiovascular events in adulthood among individuals with low childhood 25-hydroxy-vitamin D levels according to different cut points

Cut-point level vitamin D (nmol/L) in 1980	Model A (n = 3516)		Model B (n = 3194)	
	HR (95% CI)	P-value	HR (95% CI)	P-value
31 ^a (n = 299 ^b , 8.5% percentile point)	2.09 (1.25–3.50)	0.005	2.07 (1.15–3.73)	0.016
33 (n = 385, 10.9%)	1.77 (1.07–2.93)	0.025	1.76 (1.00–3.11)	0.049
35 (n = 481, 13.7%)	2.07 (1.30–3.29)	0.002	2.19 (1.30–3.69)	0.003
37 (n = 610, 17.3%)	1.77 (1.13–2.78)	0.013	1.84 (1.10–3.05)	0.019
39 (n = 725, 20.6%)	1.50 (0.96–2.34)	0.076	1.51 (0.91–2.49)	0.111
41 (n = 879, 25.0%)	1.49 (0.97–2.30)	0.069	1.50 (0.92–2.44)	0.104
43 (n = 1058, 30.1%)	1.36 (0.89–2.08)	0.152	1.36 (0.85–2.19)	0.201

Results are from Cox's regression analyses. Model A: Adjusted with age and sex. Model B: Adjusted with age, sex, and childhood measures of body mass index, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, diet (fruit consumption, vegetable consumption, fish consumption), physical activity, smoking, parental school years, and study month.

^aAll different cut points for vitamin D (i.e. 31, 33, 35, 37, 39, 41, and 43 nmol/L) were utilized in separate models.

^bn-values and percentages indicate those individuals meeting each cut point in Model A.

15.4 nmol/L. By 2018, 95 individuals (2.7%) had been diagnosed with ≥ 1 ASCVD event.⁴ The median age at first ASCVD events was 47 years (range 31–56 years).³ Table 1 (Model A) shows baseline age- and sex-adjusted hazard ratios for adulthood ASCVD events according to different childhood 25-OH-vitamin D level cut points. Significant associations were found using cut points of 37, 35, 33, and 31 nmol/L. The results were similar in a multivariable model further adjusted for multiple conventional childhood factors (Table 1, Model B). These findings remained essentially similar after propensity score matching, adjustment for adult vitamin D levels or when using vitamin D deficiency (i.e. <30 nmol/L) as a cut point (data not shown).

The current study demonstrates that low 25-OH-vitamin D levels in childhood associate with adult-onset ASCVD events, even after adjustment for conventional childhood risk factors. Observational data among adults have previously shown that individuals with low vitamin D levels have an increased risk of cardiovascular events and mortality.¹ Recently, a prospective analysis of the Alpha Omega Cohort study (69 $\pm$ 5.6 years and 78% males), over a 14-year follow-up, demonstrated that vitamin D plays an independent and combined role with physical activity in secondary prevention of CVD risk and all-cause mortality in post-myocardial infarction patients.⁵ However, the causal nature of such associations remains debated, as randomized trials and meta-analysis of the effects of vitamin D supplementation have not demonstrated a significant reduction in cardiovascular risk with increases in serum vitamin D.⁶ One explanation is that the effects of vitamin D on cardiovascular risk may operate earlier in the life course.

In our analysis, over nearly four decades of follow-up, we showed that 25-OH-vitamin levels below 37 nmol/L in childhood were associated with adult-onset ASCVD events in analyses adjusted with multiple potential confounders. From a clinical perspective, our findings suggest that suboptimal vitamin D levels in childhood could be a risk marker for adult ASCVD. This is consistent with current dietary recommendations supporting the use of supplemental vitamin D during childhood, and US guidelines suggesting optimal vitamin D levels in childhood being ≥ 50 nmol/L.⁷ However, despite of the contemporary supplement recommendations during our cohort follow-up, nearly one-fifth of our young study subjects did not reach vitamin D level cut point > 37 nmol/L, which suggests further need for optimization of vitamin D supplementation also in the paediatric population.

There are several potential pathophysiological mechanisms linking low childhood vitamin D with adult atherosclerosis. The vitamin D receptor is expressed in cells throughout the vascular system, and many of these are able to convert 25-OH-vitamin D to calcitriol, the active form of vitamin D. Calcitriol reduces inflammation, regulates the renin-angiotensin-aldosterone system, and inhibits proliferation of vascular smooth muscle,⁸ and in addition, vitamin D supplementation has been associated with slower epigenetic aging.⁹

The strengths of this study include the large, randomly selected cohort prospectively followed from childhood, the availability of childhood 25-OH-vitamin D levels, extensive data on other factors associated with atherosclerosis, and the system by which ASCVD events are ascertained in Finland. However, the potential for measurement error in baseline 25-OH-vitamin D levels is a limitation; we analysed childhood 25-OH-vitamin D from serum samples that had been collected in 1980 and stored for 30 years in -20°C . Thus, it is possible that the levels of 25-OH-vitamin D from stored samples may be inaccurate and erroneously low, although this would not have introduced a systematic bias,³ and vitamin D is considered stable under long-term storage.¹⁰ Our ethnically homogenous study population may limit the generalizability of our findings to Caucasian/White European subjects. We also recognize that the association does neither directly report causality. In addition, the study subjects within our cohort are still relatively young, and many participants have not yet reached the age at which ASCVD incidence sharply increases (typically >60 – 70 years of age), which warrants the need for continual follow-up studies when ASCVD events accumulate gradually. We had neither recorded bone metabolism disorders, calcium or phosphorus levels at baseline.

In summary, our data suggest that low 25-OH-vitamin D levels in childhood are related to higher future risk for early-onset ASCVD. The results may thus have implications in future prevention of ASCVD, and easy and cost-beneficial CVD risk mitigation via supporting optimized 25-OH-vitamin D supplementation during childhood.

Acknowledgements

The biostatisticians Irina Lisenin and Johanna Haapala are acknowledged for their statistical advice.

Author contributions

All authors contributed to the conception, design, or acquisition of the work. J.N., T.T.L., M.J., and O.R. contributed to the analysis and interpretation of data for the work. J.N. and T.T.L. drafted the manuscript. J.N., T.T.L., M.J., and O.R. critically revised the manuscript. All gave final approval and agreed to be accountable for important intellectual content of work ensuring integrity and accuracy.

Funding

The Young Finns Study has been financially supported by the Academy of Finland: grants 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 255381, 256474, 283115, 319060, 320297, 314389, 338395, 330809, 104821, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for to Aition); European Research Council (grant 742927 for MULTIEPIGEN project); and Tampere University Hospital Supporting Foundation, Finnish Society of Clinical Chemistry, and the Cancer Foundation Finland. J.N. was funded by Finnish Cultural Foundation, Varsinais-Suomi Regional Fund, and the EVO fund of Turku University Hospital. K.P. was funded by the Academy of Finland Research Fellowship (no. 322112). T.T.L. was funded by The Sakari Alhopuro Foundation.

Conflict of interest: none declared.

Data availability

The dataset supporting the conclusions of this article was obtained from the Cardiovascular Risk in YFS after submission and approval of our study plan by the YFS coordinators. The YFS dataset comprises health-related participant

data, and their use is therefore restricted under the regulations on professional secrecy (Act on the Openness of Government Activities, 612/1999) and on sensitive personal data (Personal Data Act, 523/1999, implementing the EU Q9 data protection directive 95/46/EC). Due to these legal restrictions, the data from this study cannot be stored in public repositories or otherwise made publicly available. However, data access may be permitted on a case-by-case basis upon request only. Data sharing outside the group is performed in collaboration with the YFS group and requires a data-sharing agreement. Investigators can submit an expression of interest to the chairman of the publication committee (Prof. Mika Kähönen, Tampere University, Finland).

References

1. Zhang R, Li B, Gao X, Tian R, Pan Y, Jiang Y, et al. Serum 25-hydroxyvitamin D and the risk of cardiovascular disease: dose-response meta-analysis of prospective studies. *Am J Clin Nutr* 2017;**105**:810–819.
2. Juonala M, Voipio A, Pakkala K, Viikari JS, Mikkilä V, Kähönen M, et al. Childhood 25-OH-vitamin D levels and carotid intima-media thickness in adulthood: the cardiovascular risk in young Finns study. *J Clin Endocrinol Metab* 2015;**100**:1469–1476.
3. Jacobs DR Jr, Woo JG, Sinaiko AR, Daniels SR, Ikonen J, Juonala M, et al. Childhood cardiovascular risk factors and adult cardiovascular events. *N Engl J Med* 2022;**386**:1877–1888.
4. Raitakari OT, Magnussen CG, Juonala M, Kartiosuo N, Pakkala K, Rovio S, et al. Subclinical atherosclerosis in young adults predicting cardiovascular disease: the cardiovascular risk in Young Finns study. *Atherosclerosis* 2024;**393**:117515.
5. Cruikshank E, van Pijkeren CS, Evers I, Visseren FLJ, Geleijnse JM. Vitamin D status, physical activity and long-term mortality risk after myocardial infarction: a prospective analysis in the Alpha Omega Cohort. *Eur J Prev Cardiol*; doi:10.1093/eurjpc/zwae359. Published online ahead of print 4 November 2024.
6. Barbarawi M, Kheiri B, Zayed Y. Vitamin D supplementation and cardiovascular disease risks in more than 83000 individuals in 21 randomized clinical trials: a meta-analysis. *JAMA Cardiol* 2019;**4**:765–776.
7. Taylor S. Vitamin D in toddlers, preschool children, and adolescents. *Ann Nutr Metab* 2020;**76**:30–41.
8. Carbone F, Liberale L, Libby P, Montecucco F. Vitamin D in atherosclerosis and cardiovascular events. *Eur Heart J* 2023;**44**:2078–2094.
9. Vetter VM, Sommerer Y, Kalies CH, Spira D, Bertram L, Demuth I. Vitamin D supplementation is associated with slower epigenetic aging. *Geroscience* 2022;**44**:1847–1859.
10. Hollis BW. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. *Am J Clin Nutr* 2008;**88**:507S–510S.